Health Desk—Oct 27, 2017: Medtronic plc (NYSE:MDT) has announced a strategic partnership between India Medtronic Private Limited and Diabetic Association of Bangladesh to improve outcomes for patients using diabetes care technologies. The two bodies signed a Memorandum of Understanding (MoU) recently in Mumbai of India.
The MoU was signed by Bob White, President of Medtronic, APAC, Madan Krishnan, Vice President of Medtronic Indian Sub-continent, and Prof. Dr. AK Azad Khan, President of Diabetic Association of Bangladesh.
Bangladesh is among countries with the highest number of people with diabetes. The International Diabetes Federation estimates that there are 7.1 million people with diabetes in Bangladesh and almost an equal number with undetected diabetes. This number is estimated to double by 2025.
To address the need for increased screening, diagnosis, and treatment, Medtronic and the Diabetic Association of Bangladesh jointly aim to improve access to world class diabetes care by offering diabetes care therapies and clinical expertise to patients registered with Diabetic Association of Bangladesh.
Commenting on the partnership, Bob White, President, Medtronic, APAC said, “Medtronic aims to transform diabetes care in Bangladesh by expanding access, integrating care, and improving outcomes, so people living with diabetes can enjoy greater freedom and better health. At Medtronic, we are committed to developing meaningful innovations for patients with chronic diseases — innovations that add real value in better patient outcomes at appropriate costs and lead to enhanced quality of life.”
Services, however, will begin in the Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), the comprehensive health care delivery center of the Diabetic Association of Bangladesh caring for the highest number of patients with diabetes in the world.